Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-350 in Advanced Solid Tumors (FIH Phase I/II, China)
CTR20260210Phase 2Active
- Sponsor
- LaNova Medicines
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LM-350 in Nonhematologic neoplasms, sponsored by LaNova Medicines. Started Sep 2025; status: active.
02
Drugs
LM-350
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20260210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260210.